(Press-News.org) TAMPA, Fla. – Moffitt Cancer Center will play a key role at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 30 to June 3 in Chicago. Physician-scientists and researchers from Moffitt are contributing to more than 30 oral, rapid-oral and poster presentations, offering new data and perspectives that could help shape the future of cancer care. This year’s ASCO theme, “Driving Knowledge to Action. Building a Better Future,” reflects a shared commitment to turning scientific discoveries into meaningful outcomes for patients.
Moffitt will be prominently featured at this year’s ASCO Annual Meeting, including a plenary presentation on polycythemia vera. Additional highlights include several oral presentations on melanoma, renal cell carcinoma and head and neck squamous cell carcinoma. Moffitt researchers will also present multiple posters covering a wide range of cancer types, including lung, breast, cervical and biliary tract cancers.
For a complete list of presentations, please visit Moffitt.org/ASCO.
Plenary Session:
LBA3: Results from VERIFY, a phase 3, double-blind, placebo-controlled study of rusfertide for treatment of polycythemia vera
Sunday, June 1, 2:09-2:21 p.m. CT, Hall B
Andrew Kuykendall, MD
Melanoma/Skin Cancer Late Breaking Abstracts:
LBA9505: A phase II randomized study of neoadjuvant pembrolizumab alone or in combination with vidutolimod in high-risk resectable melanoma: ECOG-ACRIN EA6194
Tuesday, June 3, 11:09-11:21 a.m. CT, S100a
Ahmad Tarhini, MD, PhD
LBA9507: A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)
Tuesday, June 3, 11:57 a.m.-12:09 p.m. CT, S100a
Zeynep Eroglu, MD
Rapid Oral Sessions:
4515: Zanzalintinib + nivolumab ± relatlimab in patients with previously untreated clear cell renal cell carcinoma: Results from an expansion cohort of the phase 1b STELLAR-002 study
Friday, May 31, 1:21-1:27 p.m. CT, Arie Crown Theater
Jad Chahoud, MD, MPH, MHA
6017: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial
Sunday, June 1, 12:12-12:18 p.m. CT, E450a
Christine Chung, MD
9514: A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma
Monday, June 2, 10:27-10:33 a.m. CT, E451
Andrew Brohl, MD
9516: Infusion product characteristics to predict response to tumor-infiltrating lymphocyte therapy in metastatic melanoma
Monday, June 2, 10:51-10:57 a.m. CT, E451
Lilit Karapetyan, MD, MSc, FACP
9008: Recognizing international medical graduates: Awards and committee membership in ASCO
Monday, June 2, 10:27-10:33 a.m. CT, E350
Karun Neupane, MD
Expert Interviews:
Moffitt experts are available to comment on a wide range of cancer research and care topics before and during the meeting by video call, phone or email. To arrange interviews, contact Kim Polacek (Kim.Polacek@Moffitt.org).
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-970-1205), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
END
Wildfire risks will continue to evolve as both society and forests change across the southeastern United States, according to a new report.
The report is one part of the Southern Forest Outlook, a project undertaken by the USDA Forest Service in partnership with the Southern Group of State Foresters to help forest managers and the public understand changing forest conditions in the South over the coming decades.
USDA Forest Service researcher Lars Pomara and his team first modeled and mapped current wildfire risks across the South, including risks to people from direct fire exposure ...
CORNELL UNIVERSITY MEDIA RELATIONS OFFICE
FOR RELEASE: May 21, 2025
Kaitlyn Serrao
607-882-1140
kms465@cornell.edu
On-site health clinics boost attendance in rural classrooms
ITHACA, N.Y. - Students miss less class time in rural upstate New York schools that host comprehensive health clinics, according to Cornell University research that is the first to confirm such benefits in rural areas. The work is also informing a legislative proposal to expand access to these clinics.
Analyzing more than 66,000 students in a four-county region over four years, the researchers found that children ...
(New York, May 22, 2025) – Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards, recognizing innovative research that will help close care gaps in clinical settings. Endowed through a generous $5 million gift from Board of Fellows member Ritu Banga and her husband, Ajay Banga, each $50,000 award supports projects aimed at improving health outcomes for populations that have historically faced systemic barriers to care.
“It is an honor to help bring to life the Banga’s vision of a health care system where everyone can experience high-quality care,” ...
Key Takeaways
Vision scientists from the School of Veterinary Medicine at the University of Pennsylvania have developed new tools—four novel promoters—to address the challenge of treating advanced stages of inherited retinal diseases that cause vision loss.
These promoters drive strong and specific gene expression in rod and cone photoreceptors even in mid-to-late stages of disease, outperforming most currently used promoters in retinal gene therapy.
These novel promoters are ideally sized for effective adeno-associated virus (AAV)-mediated delivery.
Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead ...
As the national debate intensifies around immigration, a new study from the University of California School of Global Policy and Strategy is challenging conventional wisdom about “brain drain”—the idea that when skilled workers emigrate from developing countries, their home economies suffer.
Published in Science, the paper reveals high-skilled emigration from developing countries may actually boost economic development, human capital and innovation in migrants’ countries of origin.
With the U.S. undergoing sweeping immigration ...
LOS ANGELES — Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named Top 5 “Best Hospital” in the nation for cancer care by U.S. News & World Report, will present novel cancer treatment approaches and combinations, leading-edge targeted therapies, and supportive care interventions that could reduce cancer risk and improve survival at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 ...
CAMBRIDGE, MA -- Separating crude oil into products such as gasoline, diesel, and heating oil is an energy-intensive process that accounts for about 6 percent of the world’s CO2 emissions. Most of that energy goes into the heat needed to separate the components by their boiling point.
In an advance that could dramatically reduce the amount of energy needed for crude oil fractionation, MIT engineers have developed a membrane that filters the components of crude oil by their molecular size.
“This is a whole new way of envisioning a separation process. Instead of boiling mixtures to purify them, why not separate ...
Groundbreaking Discovery
What if the human body contained a natural bioreactor capable of regenerating vital organs? A collaborative team from Wenzhou Medical University, Nanjing University, and University of Macau has redefined the spleen’s potential, transforming it into a self-sustaining hub for organ regeneration, as published in Science Translational Medicine (May 21). This breakthrough could revolutionize treatments for type 1 diabetes and beyond.
Redesigning the Spleen: From Filter to "Living Bioreactor"
Confronting ...
A leading cardiovascular disease researcher from Simon Fraser University is ringing the alarm on universal recommendations intended to improve heart health around the globe.
Cardiovascular disease (CVD) is the leading cause of death worldwide, with 80 per cent of deaths occurring in low- and middle-income countries. However, international heart-health guidelines are primarily based on research from high-income countries and often overlook upstream causes of CVD, says Scott Lear, a health sciences professor at SFU and the Pfizer/Heart & Stroke Foundation Chair in Cardiovascular Prevention Research.
“The world extends beyond high-income countries when we think ...
A new study from UBC Okanagan says students appear to be using generative artificial intelligence (GenAI) responsibly, and as a way to speed up tasks, not just boost their grades.
Dr. Meaghan MacNutt, who teaches professional ethics in the UBCO School of Health and Exercise Sciences (HES), recently published a study in Advances in Physiology Education. Published this month, the paper—titled Reflective writing assignments in the era of GenAI: student behaviour and attitudes suggest utility, not futility—contradicts ...
